Clinical Trial Update: Sintilimab With Chemotherapy Plus PEG-rhG-GSF for Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma [Phase 3]

View source ↗

Summary

A Phase 3 trial is evaluating Sintilimab combined with chemotherapy and PEG-rhG-GSF as neoadjuvant therapy for Esophageal Squamous Cell Carcinoma; the study is …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• PEG-rhG-GSF (Pegylated recombinant human granulocyte colony-stimulating factor)
• Tyvyt (Sintilimab) (Sintilimab)

Snippet

Sponsor: The First Affiliated Hospital with Nanjing Medical University | Conditions: Esophageal Squamous Cell Carcinoma | Phase 3 | Status: RECRUITING